John F. Lyons

5.9k citations

81 papers · 4.3k · 2 hit papers · h-index 32

Impact in

Hematology top 2%
- Acute Myeloid Leukemia Research
Oncology top 2%
- Cancer-related Molecular Pathways

Papers in

Molecular Biology 48
- Heat shock proteins research 9
- Melanoma and MAPK Pathways 7
- Epigenetics and DNA Methylation 7
- Protein Degradation and Inhibitors 6
Oncology 21
- Cancer-related Molecular Pathways 12

Co-authors: Kurt Grünewald (3 shared papers)Hans G. Feichtinger (4 shared papers)Gideon Bollag (2 shared papers)Orlo H. Clark (2 shared papers)Henry R. Bourne (2 shared papers)Frank McCormick (2 shared papers)Barbara Hibner (2 shared papers)S M Wilhelm (1 shared paper)
Journals: Blood (17 papers)Molecular Cancer Therapeutics (8 papers)Clinical Cancer Research (5 papers)Cancer Research (4 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

John F. Lyons

78 papers receiving 4.2k citations

John F. Lyons's Hit Papers

align trajectories log scale

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies 2003 · 631 citations

Peers

Countries citing papers authored by John F. Lyons

Since Specialization

Citations

This map shows the geographic impact of John F. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Lyons more than expected).

Fields of papers citing papers by John F. Lyons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Lyons. The network helps show where John F. Lyons may publish in the future.

Co-authors

The 25 scholars most cited alongside John F. Lyons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John F. Lyons Line = papers co-authored together John F. Lyons links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Two G Protein Oncogenes in Human Endocrine Tumors Science ·John F. Lyons, Claudia A. Landis, Griffith Harsh, Lucia Vallar, Kurt Grünewald, Hans G. Feichtinger, Quan‐Yang Duh, Orlo H. Clark, Ernest S. Kawasaki, Henry R. Bourne, Frank McCormick Hit paper breakdown →	1990	827
2	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood ·Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis J. Giles, Rajan K. Mannari, Deborah A. Thomas, Stefan Faderl, Emel Bayar, John F. Lyons, C Rosenfeld, Jörge E. Cortes, Hagop M. Kantarjian Hit paper breakdown →	2003	631
3	Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. PubMed ·M. Jane Arboleda, John F. Lyons, Fairooz F. Kabbinavar, Mark R. Bray, Bryan E. Snow, Raul Ayala, Mordechai Danino, Beth Y. Karlan, Dennis J. Slamon	2003	353
4	Discovery of a novel Raf kinase inhibitor. Endocrine Related Cancer ·John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon Bollag	2001	314
5	High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas International Journal of Cancer ·Kurt Grünewald, John F. Lyons, Anja Fröhlich, Hans G. Feichtinger, Richard A. Weger, G. Schwab, Johannes W.G. Janssen, Claus R. Bartram	1989	244
6	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Molecular Cancer Therapeutics ·Matthew Squires, Ruth E. Feltell, Nicola G. Wallis, Edward J. Lewis, Donna-Michelle Smith, David M. Cross, John F. Lyons, Neil T. Thompson	2009	134
7	Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes Blood ·John F. Lyons, JW Janssen, CR Bartram, Mark Layton, GJ Mufti	1988	102
8	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations Clinical Cancer Research ·Nicholas Pulliam, Fang Fang, Ali Özeş, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John F. Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V. Rassool, Kathy D. Miller, Kenneth P. Nephew	2018	95
9	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Clinical Cancer Research ·Fang Fang, Joanne M. Munck, Jessica Tang, Pietro Taverna, Yinu Wang, David F. Miller, Jay Pilrose, Gavin Choy, Mohammad Azab, Katherine S. Pawelczak, Pamela S. VanderVere-Carozza, Michael Wagner, John F. Lyons, Daniela Matei, John J. Turchi, Kenneth P. Nephew	2014	81
10	First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan	2014	75
11	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach Bioorganic & Medicinal Chemistry Letters ·Roger A. Smith, J A Barbosa, Cheri L. Blum, Mark A. Bobko, Yolanda Caringal, Robert Dally, Jeffrey S. Johnson, Michael Katz, Nancy Kennure, Jill Kingery-Wood, Wendy Lee, Timothy B. Lowinger, John F. Lyons, Vivienne Marsh, Daniel H. Rogers, Stephen G. Swartz, Tracy L. Walling, Hanno Wild	2001	70
12	Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications World Journal of Surgery ·Peter E. Goretzki, John F. Lyons, Sandrina Stacy‐Phipps, Werner Rosenau, Michael J. Demeure, Orlo H. Clark, Frank McCormick, H. D. Röher, Henry R. Bourne	1992	68
13	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models Molecular Cancer Therapeutics ·Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodríguez-López, Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis	2014	66
14	The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer Cancer Science ·Brent Graham, Jayne Curry, Tomoko Smyth, Lynsey Fazal, Ruth E. Feltell, Isobel Harada, Joe Coyle, Brian Williams, Matthias Reule, Hayley C. Angove, David M. Cross, John F. Lyons, Nicola G. Wallis, Neil T. Thompson	2011	65
15	Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma Epigenetics ·Simone Jueliger, John F. Lyons, Sara Cannito, Illar Pata, Pille Pata, Marianna Shkolnaya, Oriana Lo Re, Marion Peyrou, Francesc Villarroya, Valerio Pazienza, Francesca Rappa, Francesco Cappello, Mohammad Azab, Pietro Taverna, Manlio Vinciguerra	2016	65
16	Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells Blood ·Ruriko Tanaka, Matthew Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver G. Ottmann, Taira Maekawa	2010	56
17	ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth Molecular Cancer Therapeutics ·George A. Ward, Edward J. Lewis, Jong Sook Ahn, Christopher N. Johnson, John F. Lyons, Vanessa Martins, Joanne M. Munck, Sharna J. Rich, Tomoko Smyth, Neil T. Thompson, Pamela A. Williams, Nicola E. Wilsher, Nicola G. Wallis, Gianni Chessari	2018	53
18	A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies Annals of Oncology ·Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, David Olmos, Timothy A. Yap, Matthew Squires, Sara Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Judson	2011	52
19	AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth Molecular Cancer Therapeutics ·Kyla M. Grimshaw, Lisa-Jane K. Hunter, Timothy A. Yap, Simon P. Heaton, Mike I. Walton, Steven J. Woodhead, Lynsey Fazal, Matthias Reule, Thomas G. Davies, Lisa C. A. Seavers, Victoria Lock, John F. Lyons, Neil T. Thompson, Paul Workman, Michelle D. Garrett	2010	50
20	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models Molecular Cancer Therapeutics ·Tomoko Smyth, Thomas Van Looy, Jayne Curry, Ana M. Rodrı́guez-López, Agnieszka Woźniak, Mei‐Jun Zhu, Rachel Donsky, Jennifer G. Morgan, Mark Mayeda, Jonathan A. Fletcher, Patrick Schöffski, John F. Lyons, Neil T. Thompson, Nicola G. Wallis	2012	49

About John F. Lyons

John F. Lyons is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Hematology and Cell Biology, having authored 81 papers that have together received 4.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (12 papers), Acute Myeloid Leukemia Research (10 papers), Microtubule and mitosis dynamics (10 papers), Heat shock proteins research (9 papers), Melanoma and MAPK Pathways (7 papers), Chronic Lymphocytic Leukemia Research (7 papers), Epigenetics and DNA Methylation (7 papers) and Protein Degradation and Inhibitors (6 papers). The work is most often cited by research in Hematology (577 citations), Oncology (1.3k citations), Molecular Biology (2.7k citations), Cancer Research (551 citations) and Genetics (321 citations). John F. Lyons has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Kurt Grünewald, Hans G. Feichtinger, Gideon Bollag, Orlo H. Clark, Henry R. Bourne, Frank McCormick, Barbara Hibner, S M Wilhelm, Ernest S. Kawasaki and Claudia A. Landis. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

John F. Lyons

Impact in

Papers in i

In The Last Decade

John F. Lyons

John F. Lyons's Hit Papers

Peers

Countries citing papers authored by John F. Lyons

Fields of papers citing papers by John F. Lyons

All Works

About John F. Lyons

Explore authors with similar magnitude of impact

Papers in